RANITIDINE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H22N4O3S.ClH
Molecular Weight	350.8663
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CNC(=CN(=O)=O)NCCSCc1ccc(CN(C)C)o1.Cl

InChI

InChIKey=GGWBHVILAJZWKJ-UHFFFAOYSA-N

InChI=1S/C13H22N4O3S.ClH/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3;/h4-5,9,14-15H,6-8,10H2,1-3H3;1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.4609
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C13H22N4O3S
Molecular Weight	314.4054
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2667937,6309467

Ranitidine, a histamine H2-receptor antagonist, is now well established as a potent inhibitor of gastric acid secretion effective in the treatment and prophylaxis of gastrointestinal lesions aggravated by gastric acid secretion.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Histamine H2 receptor 43 Target ID: P25102 Gene ID: 25461.0 Gene Symbol: Hrh2 Target Organism: Rattus norvegicus (Rat) Sources: http://www.pnas.org/content/93/13/6802.full.pdf	Antagonist 2575	0.14 µM [Ki]
Histamine H2 receptor 43 Target ID: P47747 Gene ID: NA Gene Symbol: HRH2 Target Organism: Cavia porcellus (Guinea pig) Sources: https://www.ncbi.nlm.nih.gov/pubmed/9205741	Antagonist 2575	0.19 µM [Ki]
Histamine H2 receptor 43 Target ID: P25021 Gene ID: 3274.0 Gene Symbol: HRH2 Target Organism: Homo sapiens (Human) Sources: http://ca.gsk.com/media/592906/zantac.pdf	Antagonist 2575

Conditions

Condition	Modality	Highest Phase	Product
Duodenal ulcer 43 Sources: http://ca.gsk.com/media/592906/zantac.pdf	Primary	Approved 8043	ZANTAC 150 Approved Use ZANTAC® (ranitidine hydrochloride) Tablets and Injection are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion and acid output is desirable. These include the following: • the treatment of nonsteroidal anti-inflammatory drug (NSAID)- induced lesions, both ulcers and erosions, and their gastrointestinal (GI) symptoms and the prevention of their recurrence; • the prophylaxis of GI hemorrhage from stress ulceration in seriously ill patients; • the prophylaxis of recurrent hemorrhage from bleeding ulcers; • the prevention of Acid Aspiration Syndrome from general anaesthesia in patients considered to be at risk for this, including obstetrical patients in labour, and obese patients. In addition, ZANTAC® is indicated for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration. Launch Date 4.23964803E11
Gastric ulcer 61 Sources: http://ca.gsk.com/media/592906/zantac.pdf	Primary	Approved 8043	ZANTAC 150 Approved Use ZANTAC® (ranitidine hydrochloride) Tablets and Injection are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion and acid output is desirable. These include the following: • the treatment of nonsteroidal anti-inflammatory drug (NSAID)- induced lesions, both ulcers and erosions, and their gastrointestinal (GI) symptoms and the prevention of their recurrence; • the prophylaxis of GI hemorrhage from stress ulceration in seriously ill patients; • the prophylaxis of recurrent hemorrhage from bleeding ulcers; • the prevention of Acid Aspiration Syndrome from general anaesthesia in patients considered to be at risk for this, including obstetrical patients in labour, and obese patients. In addition, ZANTAC® is indicated for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration. Launch Date 4.23964803E11
Gastroesophageal reflux disease 45 Sources: http://ca.gsk.com/media/592906/zantac.pdf	Primary	Approved 8043	ZANTAC 150 Approved Use ZANTAC® (ranitidine hydrochloride) Tablets and Injection are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion and acid output is desirable. These include the following: • the treatment of nonsteroidal anti-inflammatory drug (NSAID)- induced lesions, both ulcers and erosions, and their gastrointestinal (GI) symptoms and the prevention of their recurrence; • the prophylaxis of GI hemorrhage from stress ulceration in seriously ill patients; • the prophylaxis of recurrent hemorrhage from bleeding ulcers; • the prevention of Acid Aspiration Syndrome from general anaesthesia in patients considered to be at risk for this, including obstetrical patients in labour, and obese patients. In addition, ZANTAC® is indicated for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration. Launch Date 4.23964803E11
Zollinger-Ellison syndrome 14 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018703s065,019675s031,020251s016lbl.pdf	Primary	Approved 8043	ZANTAC 150 Approved Use ZANTAC® (ranitidine hydrochloride) Tablets and Injection are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion and acid output is desirable. These include the following: • the treatment of nonsteroidal anti-inflammatory drug (NSAID)- induced lesions, both ulcers and erosions, and their gastrointestinal (GI) symptoms and the prevention of their recurrence; • the prophylaxis of GI hemorrhage from stress ulceration in seriously ill patients; • the prophylaxis of recurrent hemorrhage from bleeding ulcers; • the prevention of Acid Aspiration Syndrome from general anaesthesia in patients considered to be at risk for this, including obstetrical patients in labour, and obese patients. In addition, ZANTAC® is indicated for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration. Launch Date 4.23964803E11

C_max

Value	Dose	Co-administered	Analyte	Population
440 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018703s068,019675s035,020251s019lbl.pdf	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		RANITIDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
948.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6094785/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:		RANITIDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.69 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6094785/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:		RANITIDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018703s068,019675s035,020251s019lbl.pdf	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		RANITIDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
85% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018703s068,019675s035,020251s019lbl.pdf	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		RANITIDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6329583/	healthy, adult n = 136 Health Status: healthy Age Group: adult Sex: M+F Population Size: 136 Sources: https://pubmed.ncbi.nlm.nih.gov/6329583/	Sources: https://pubmed.ncbi.nlm.nih.gov/6329583/
1500 mg single, oral Overdose Dose: 1500 mg Route: oral Route: single Dose: 1500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/28425352/	unknown, children n = 517 Health Status: unknown Age Group: children Sex: unknown Population Size: 517 Sources: https://pubmed.ncbi.nlm.nih.gov/28425352/	Sources: https://pubmed.ncbi.nlm.nih.gov/28425352/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1467 substrate 1601		inhibitor 1702 substrate 1118

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT1 480 OCT2 594 OCT3 140 MATE1 290 MATE2 251 CYP3A 191 CYP1A2 1383	OCT1 302 OCT2 316 OCT3 75 P-gp 1400 FMO3 64 FMO1 16 CYP1A2 972 CYP2A6 485 CYP2C19 910 CYP2E1 606

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1532	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/10223772/	no
CYP2D6 1738	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/10223772/	no
CYP3A 271	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/10223772/	no	no (co-administration study) Comment: Ranitidine has no effect on midazolam exposure Sources: https://pubmed.ncbi.nlm.nih.gov/10223772/
OCT3 140	inhibitor 3045 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16141367	weak [IC50 290 uM]
CYP3A4 1772	inhibitor 3045 Sources: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers	weak
OCT2 595	inhibitor 3045 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16141367	yes [IC50 114 uM]
MATE1 292	inhibitor 3045 Sources: http://www.ncbi.nlm.nih.gov/pubmed/20053795	yes [IC50 18.9 uM]
OCT1 495	inhibitor 3045 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16141367	yes [IC50 28 uM]
MATE2 251	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/19164462/	yes [Ki 25 uM]

Drug as victim

Target	Modality	Activity
FMO3 64	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/11128045/	major
FMO1 16	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/11128045/	minor
OCT2 316	substrate 3113 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16141367	minor
CYP2A6 485	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/11128045/	no
CYP2E1 606	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/11128045/	no
CYP3A4 1601	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/11128045/	no
OCT3 75	substrate 3113 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16141367	no
CYP1A2 972	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/11128045/	yes
CYP2C19 910	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/11128045/	yes
CYP2D6 1118	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/11128045/	yes
OCT1 302	substrate 3113 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16141367	yes
P-gp 1400	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/9862768/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:8776	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8776
ChemicalBook	CB5480252	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5480252
MolPort	MolPort-003-666-370	https://www.molport.com/shop/molecule-link/MolPort-003-666-370
ZINC	ZINC000001530728	http://zinc15.docking.org/substances/ZINC000001530728

PubMed

Title	Date	PubMed
Histamine H2 antagonists and the nervous system.	1985 Dec	4072863
Comparison of ranitidine and high-dose antacid in the treatment of prepyloric or duodenal ulcer. A double-blind controlled trial.	1985 Jan	3887547
Bradycardia and neurologic disorders associated with ranitidine in a child.	1985 May	3984961
Mental confusion as a side effect of ranitidine.	1986 Feb	3946668
Depression associated with ranitidine.	1986 Jul	3717435
Myofascial headache. Exacerbation of symptoms due to diflunisal and ranitidine therapy. A case report.	1987 Aug	3308026
Histamine and hepatic glutathione in the mouse.	1987 May 25	2884542
Mania associated with intravenous ranitidine therapy.	1987 Nov	3500517
Fatal renal and hepatic toxicity after treatment with diltiazem.	1987 Nov 14	3120959
Famotidine-associated mental confusion in elderly patients.	1988 Dec	3243179
Mania-like episodes associated with ranitidine.	1988 Feb	3341479
First-degree atrioventricular block in a young duodenal ulcer patient treated with a standard oral dose of ranitidine.	1988 Jul	3177090
Reversible chorea due to ranitidine and cimetidine.	1988 Jul 16	2899203
Ranitidine and bradycardia.	1988 Mar	3341694
Ranitidine-induced confusion with concomitant morphine.	1988 Nov	3234261
Cardiac arrest associated with ranitidine.	1989 Aug 19	2507055
A dog model for acetaminophen-induced fulminant hepatic failure.	1989 Feb	2910762
Famotidine and ranitidine, but not cimetidine, cause severe, disabling headache.	1989 Feb	2563629
Mechanism of ranitidine associated anemia.	1989 Jun	2735342
Ranitidine-induced chest pain.	1989 Mar	2718500
Histamine release in the isolated vascularly perfused stomach of the rat: regulation by autoreceptors.	1989 Mar	2470453
Effect of ranitidine on acetaminophen-induced hepatotoxicity in dogs.	1990 Mar	2307085
Effects of histamine H2-receptor blockade on the cardiovascular reflex response to lower-body negative pressure in man.	1990 May	1972605
Seizures during concomitant treatment with theophylline and ranitidine: a case report.	1990 Oct-Dec	2093363
Ranitidine-associated delirium.	1990 Winter	2300661
Effects of antihistaminics on locomotor activity in mice. Comparison with opiate and amphetamine-induced hyperactivity.	1991	1676005
Ranitidine and depression.	1991 Sep	1958166
Role of histamine in airway remodeling of asthmatic guinea pig.	2005 Dec 25	16344897
Antisecretory and antiulcer activity of Asparagus racemosus Willd. against indomethacin plus phyloric ligation-induced gastric ulcer in rats.	2006	17135157
Unique gene expression and hepatocellular injury in the lipopolysaccharide-ranitidine drug idiosyncrasy rat model: comparison with famotidine.	2006 Apr	16415329
Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes.	2006 Aug	16723495
In vitro availability of metformin in presence of h(2) receptor antagonists.	2006 Jan	16632449
Inlet patch of gastric mucosa in upper esophagus causing chronic cough and vocal cord dysfunction.	2006 Jan	16440542
Attenuation of indomethacin- and HCl/ethanol-induced oxidative gastric mucosa damage in rats by kolaviron, a natural biflavonoid of Garcinia kola seed.	2006 Jan	16397915
Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine.	2006 May	16401727
Gastroprotective and antioxidant effects of amiodarone on indomethacin-induced gastric ulcers in rats.	2007 Nov	18087811
The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury.	2007 Nov	17698507
Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats.	2007 Sep	17895592
Gastroprotective and anti-oxidative properties of ascorbic acid on indomethacin-induced gastric injuries in rats.	2008 Winter	18726076
Severe hypomagnesaemia due to lansoprazole.	2009	22180759
Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity.	2009 Jun 15	19362101
Protective effect of histamine H2 receptor antagonist ranitidine against rotenone-induced apoptosis.	2009 Nov	19723537
Drug-induced aseptic meningitis, sensorineural hearing loss and vestibulopaty.	2010 Sep	20977110
Two cases of h(2)-receptor antagonist hypersensitivity and cross-reactivity.	2011 Apr	21461253
Hepatoprotective, antinociceptive and antioxidant activities of cimetidine, ranitidine and famotidine as histamine H2 receptor antagonists.	2011 Feb	20070855
Attenuation of stress-induced gastric lesions by lansoprazole, PD-136450 and ranitidine in rats.	2011 Mar	21116686
Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764).	2011 Nov 10	21928839
The mediation of the central histaminergic system in the pressor effect of intracerebroventricularly injected melittin, a phospholipase A2 activator, in normotensive rats.	2012 Oct-Nov	22995146
Gastroprotective effects of goniothalamin against ethanol and indomethacin-induced gastric lesions in rats: Role of prostaglandins, nitric oxide and sulfhydryl compounds.	2014 Dec 5	25451594
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.	2014 Jan	24085192

Patents

Sample Use Guides

In Vivo Use Guide

150 mg twice daily (tablets or syrup)

Route of Administration: Oral

In Vitro Use Guide

10uM ranitidine partially suppresses histamine-elicited signaling in human tubular epithelial cells

Substance Class	Chemical Created by `admin` on `Fri Jun 25 20:53:59 UTC 2021` Edited by `admin` on `Fri Jun 25 20:53:59 UTC 2021`
Record UNII	BK76465IHM
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RANITIDINE HYDROCHLORIDE

Common Name

English

ZANTAC

Brand Name

English

AH 19065

Code

English

RANITIDINE HYDROCHLORIDE [JAN]

Common Name

English

RANITIDINE HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

RANITIDINE HYDROCHLORIDE [USP-RS]

Common Name

English

RANITIDINE HYDROCHLORIDE [EP]

Common Name

English

RANITIDINE HYDROCHLORIDE [MI]

Common Name

English

AH-19065

Code

English

RANITIDINE HYDROCHLORIDE [MART.]

Common Name

English

TALADINE

Brand Name

English

RANITIDINE HCL

Common Name

English

RANITIDINE HYDROCHLORIDE [WHO-DD]

Common Name

English

RANITIDINE HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

RANITIDINE HYDROCHLORIDE [VANDF]

Common Name

English

RANITIDINE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

N-(2-(((5-((DIMETHYLAMINO)METHYL)-2-FURANYL)METHYL)THIO)ETHYL)-N'-METHYL-2-NITRO-1,1-ETHENEDIAMINE, HYDROCHLORIDE

Systematic Name

English

1,1-ETHENEDIAMINE, N-(2-(((5-((DIMETHYLAMINO)METHYL)-2-FURANYL)METHYL)THIO)ETHYL)-N'-METHYL-2-NITRO-, MONOHYDROCHLORIDE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29702

Created by admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021

Code System Code Type Description

WIKIPEDIA

Ranitidine hydrochloride

Created by admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021

PRIMARY

FDA UNII

BK76465IHM

Created by admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021

PRIMARY

RXCUI

203136

Created by admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021

PRIMARY

RxNorm

MERCK INDEX

M9498

Created by admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021

PRIMARY

Merck Index

PUBCHEM

47909

Created by admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021

PRIMARY

NCI_THESAURUS

C66506

Created by admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021

PRIMARY

USP_CATALOG

1598405

Created by admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021

PRIMARY

USP-RS

ECHA (EC/EINECS)

266-333-0

Created by admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021

PRIMARY

ChEMBL

CHEMBL1790041

Created by admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021

PRIMARY

EVMPD

SUB04203MIG

Created by admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021

PRIMARY

CAS

66357-59-3

Created by admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021

PRIMARY

DRUG BANK

DBSALT000487

Created by admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021

PRIMARY

Related Record Type Details


					884KT10YB7

RANITIDINE

PARENT -> SALT/SOLVATE


					BK76465IHM

RANITIDINE HYDROCHLORIDE

BASIS OF STRENGTH->SUBSTANCE

Interaction Type:

ASSAY (TITRATION)

Qualification:

EP

Amount:


					BK76465IHM

RANITIDINE HYDROCHLORIDE

BASIS OF STRENGTH->SUBSTANCE

Interaction Type:

ASSAY (HPLC)

Qualification:

USP

Amount:

Related Record Type Details


					K131L1Z4KY

RANITIDINE N-OXIDE

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP


					VUN945A63D

N-(2-(((5-((DIMETHYLAMINO)METHYL)FURAN-2-YL)METHYL)SULFANYL)ETHYL)-2-NITROACETAMIDE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					K131L1Z4KY

RANITIDINE N-OXIDE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					TK8SB999BQ

RANITIDINE S-OXIDE

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP


					J1993OKZ0C

2,2'-METHYLENE BIS(RANITIDINE)

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					FL17V7RS6Z

N-METHYLNITROACETAMIDE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					96O88RC7HA

5-((DIMETHYLAMINO)METHYL)-2-FURANMETHANOL

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					TK8SB999BQ

RANITIDINE S-OXIDE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					S8W8I89W43

5-(((2-AMINOETHYL)THIO)METHYL)-N,N-DIMETHYL-2-FURANMETHANAMINE

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP


					F01WAX6X3P

N,N'-BIS(2-(((5-((DIMETHYLAMINO)METHYL)FURAN-2-YL)METHYL)SULFANYL)ETHYL)-2-NITROETHENE-1,1-DIAMINE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					C21M8X095K

1,1'-N-(METHYLENEBIS(SULFANEDIYLETHYLENE))BIS(N'-METHYL-2-NITROETHENE-1,1-DIAMINE)

IMPURITY -> PARENT

Comments:

For the calculation of contents, multiply the peak areas by 0.2

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					J1993OKZ0C

2,2'-METHYLENE BIS(RANITIDINE)

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP


					F01WAX6X3P

N,N'-BIS(2-(((5-((DIMETHYLAMINO)METHYL)FURAN-2-YL)METHYL)SULFANYL)ETHYL)-2-NITROETHENE-1,1-DIAMINE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					OM0HA3681J

N-METHYL-1-(METHYLTHIO)-2-NITROETHENAMINE

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP


					96O88RC7HA

5-((DIMETHYLAMINO)METHYL)-2-FURANMETHANOL

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP


					VUN945A63D

N-(2-(((5-((DIMETHYLAMINO)METHYL)FURAN-2-YL)METHYL)SULFANYL)ETHYL)-2-NITROACETAMIDE

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP


					S8W8I89W43

5-(((2-AMINOETHYL)THIO)METHYL)-N,N-DIMETHYL-2-FURANMETHANAMINE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:

Related Record Type Details


					884KT10YB7

RANITIDINE

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/2667937,6309467

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2667937,6309467

C_max

T_1/2

F_unbound

Drug as perpetrator